Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.47 USD
Change Today -0.11 / -6.96%
Volume 623.4K
STXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

stereotaxis inc (STXS) Snapshot

Open
$1.60
Previous Close
$1.58
Day High
$1.60
Day Low
$1.37
52 Week High
09/4/14 - $3.61
52 Week Low
08/24/15 - $0.65
Market Cap
31.0M
Average Volume 10 Days
1.7M
EPS TTM
$-0.18
Shares Outstanding
21.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEREOTAXIS INC (STXS)

Related News

No related news articles were found.

stereotaxis inc (STXS) Related Businessweek News

No Related Businessweek News Found

stereotaxis inc (STXS) Details

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and ablation devices designed to enhance interventional procedures. The company also offers Odyssey solution, which provides integrated real-time information solution to manage, control, record, and share procedures across networks worldwide. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters; and Pegasus coronary guidewire for cardiology procedures. Further, the company offers V-CAS catheter and V-CAS Deflect integrated catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. Stereotaxis, Inc. has strategic alliances with Siemens AG Medical Solutions; Philips Medical Systems; and Biosense Webster, Inc. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

133 Employees
Last Reported Date: 03/16/15
Founded in 1990

stereotaxis inc (STXS) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $662.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $337.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $423.8K
Vice President of Human Resources
Total Annual Compensation: $315.0K
Senior Vice President of Marketing & Business...
Total Annual Compensation: $435.0K
Compensation as of Fiscal Year 2014.

stereotaxis inc (STXS) Key Developments

Stereotaxis, Inc. Announces Results of Seven-Year Clinical Study

Stereotaxis Inc. announced the results of a seven-year clinical study, which provides significant findings in terms of the Stereotaxis remote magnetic navigation platform's success in ventricular tachycardia (VT) ablations compared to both contact force sensing and other manual catheters. A total of 239 patients who underwent VT ablation with CF catheters, other manual catheters or the Stereotaxis Niobe® remote magnetic navigation system were included in this single-center, cohort study from January 2007 until March 2014. The higher acute procedural success 86% was achieved in the patient group using the Niobe system, compared to a success rate of 71% for the CF and manual groups. Major complications occurred in 1.2% of Niobe patients versus 10% of CF patients and 2.7% of manual patients. Moreover, the recurrence rate was lowest in the Niobe group, which had the most rigorous follow-up time of 29 months compared to 18 and 25 months for the CF and manual groups, respectively. Overall, 42% of Niobe patients had a recurrence during follow-up, versus 59% of CF patients and 57% of manual patients. Complete study results can be accessed online in the Journal of Cardiovascular Electrophysiology (DOI: 10.1111/jce.12762, 2015).

Stereotaxis Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Stereotaxis Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $9,664,250 compared to $8,047,537 a year ago. Operating loss was $1,722,326 compared to $2,289,633 a year ago. Net loss was $1,538,687 or $0.07 per basic and diluted share compared to $1,941,479 or $0.10 per basic and diluted share a year ago. Excluding mark-to-market warrant revaluation, net loss would have been $2.5 million or $0.12 per share in the second quarter of 2015 and $3.1 million or $0.16 per share in the 2014 second quarter. For the six months, the company reported total revenue of $19,195,276 compared to $16,402,207 a year ago. Operating loss was $3,136,605 compared to $4,518,625 a year ago. Net loss was $4,674,268 or $0.22 per basic and diluted share compared to $6,081,326 or $0.31 per basic and diluted share a year ago. Excluding mark-to-market warrant revaluation, the first half of 2015 net loss would have been $4.8 million or $0.23 per share, and the first half 2014 net loss would have been $6.2 million or $0.32 per share.

Stereotaxis Inc. to Report Q2, 2015 Results on Aug 04, 2015

Stereotaxis Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STXS:US $1.47 USD -0.11

STXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bovie Medical Corp $2.29 USD 0.00
Corindus Vascular Robotics Inc $3.35 USD -0.09
Hansen Medical Inc $0.53 USD -0.033
LeMaitre Vascular Inc $13.05 USD +0.44
Vascular Solutions Inc $34.15 USD +0.45
View Industry Companies
 

Industry Analysis

STXS

Industry Average

Valuation STXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEREOTAXIS INC, please visit www.stereotaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.